BioCentury | Jul 13, 2015

Accelerating investor interest

Advanced Accelerator Applications S.A. hopes that a trio of U.S. crossover investors will help the nuclear medicine play garner a better valuation if it takes another shot at tapping the U.S. IPO market. On June...
BioCentury | Jun 16, 2008

GLP-1 bragging rights

Novo Nordisk A/S released data at last week's American Diabetes Association meeting showing that its once daily liraglutide was at least as good as twice-daily Byetta exenatide from Amylin Pharmaceuticals Inc. But Amylin thinks that...
BioCentury | Jan 1, 2007

2007 Financial Markets Preview: M&A upside

...still beat biotech, ending the year with an 8% gain. That was not much to brag...
BioCentury | Jan 14, 2002

Ebb & Flow

'The great tragedy of science - the slaying of a beautiful hypothesis by an ugly fact.' - Biologist Thomas Henry Huxley It was hard to ignore the level of swagger and hubris among company executives at the...
BioCentury | Apr 24, 2000
Politics, Policy & Law

Bragging rights

OXFORD - When Germany set out in the mid-1990s to take leadership of European biotech, few believed it was possible. But the publication last week of Ernst & Young's seventh annual European Life Sciences Report indicates...
Items per page:
1 - 5 of 5